

Navigating the endocrine suitability spectrum in HR+ mBC: Tailoring patient care from ET-based approaches to ADCs

Thursday 15th May 2025, 12:45 – 13:45 (CEST)
Room 13, International Congress Center Messe,
Munich, Germany

“Get your questions ready!”

Join us as we delve into case studies to explore evolving approaches to personalise treatments for patients with HR+ mBC

Join us for an interactive case-based discussion to:

- Discuss the recent and ongoing advancements from mBC clinical trials that look to extend the benefit of ET-based regimens and their implications for improving patient outcomes
- Explore how ADCs are transforming approaches to patient care across the mBC disease spectrum

Faculty



Prof. Sibylle Loibl (Chair)
Goethe University of Frankfurt,
Germany



Prof. François-Clément Bidard
Institut Curie,
France



Dr Sara Tolaney
Dana-Farber Cancer Institute,
US

Agenda

12:45 – 12:50	HR-positive mBC: Addressing a dynamic and heterogeneous disease	Sibylle Loibl
12:50 – 13:05	Exploring evolving ET-based regimens: Recent advances and future directions	François-Clément Bidard
13:05 – 13:15	Case-based discussion: Personalising ET-based therapy	François-Clément Bidard Moderated by Sibylle Loibl
13:15 – 13:30	ADCs: Expanding options beyond ET	Sara Tolaney
13:30 – 13:40	Case-based discussion: Changing treatment modalities in HR-positive mBC	Sara Tolaney Moderated by Sibylle Loibl
13:40 – 13:45	Summary and close	Sibylle Loibl